Cargando…

Re-Use of Established Drugs for Anti-Metastatic Indications

Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate s...

Descripción completa

Detalles Bibliográficos
Autores principales: Entschladen, Frank, Thyssen, Dane A., Drell, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810087/
https://www.ncbi.nlm.nih.gov/pubmed/26771645
http://dx.doi.org/10.3390/cells5010002
_version_ 1782423720461074432
author Entschladen, Frank
Thyssen, Dane A.
Drell, David W.
author_facet Entschladen, Frank
Thyssen, Dane A.
Drell, David W.
author_sort Entschladen, Frank
collection PubMed
description Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication.
format Online
Article
Text
id pubmed-4810087
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48100872016-04-04 Re-Use of Established Drugs for Anti-Metastatic Indications Entschladen, Frank Thyssen, Dane A. Drell, David W. Cells Review Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication. MDPI 2016-01-12 /pmc/articles/PMC4810087/ /pubmed/26771645 http://dx.doi.org/10.3390/cells5010002 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Entschladen, Frank
Thyssen, Dane A.
Drell, David W.
Re-Use of Established Drugs for Anti-Metastatic Indications
title Re-Use of Established Drugs for Anti-Metastatic Indications
title_full Re-Use of Established Drugs for Anti-Metastatic Indications
title_fullStr Re-Use of Established Drugs for Anti-Metastatic Indications
title_full_unstemmed Re-Use of Established Drugs for Anti-Metastatic Indications
title_short Re-Use of Established Drugs for Anti-Metastatic Indications
title_sort re-use of established drugs for anti-metastatic indications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810087/
https://www.ncbi.nlm.nih.gov/pubmed/26771645
http://dx.doi.org/10.3390/cells5010002
work_keys_str_mv AT entschladenfrank reuseofestablisheddrugsforantimetastaticindications
AT thyssendanea reuseofestablisheddrugsforantimetastaticindications
AT drelldavidw reuseofestablisheddrugsforantimetastaticindications